CP
TEVA icon

Centerbridge Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Centerbridge Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100,000
Closed -$965K – 59
2020
Q4 		$965K Hold
100,000
– – 0.08% 19
2020
Q3 		$901K Hold
100,000
– – 0.1% 12
2020
Q2 		$1.23M Hold
100,000
– – 0.26% 15
2020
Q1 		$898K Buy
+100,000
New +$1.02M 0.22% 19

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Centerbridge Partners's TEVA Position: Q1 2021 in Review

Centerbridge Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2021, closing a stake of 100,000 shares — an estimated $965K sold.

Centerbridge Partners first reported a position in TEVA in Q1 2020 and held it in 4 quarters. The position peaked at $1.23M in Q2 2020. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

  • Centerbridge Partners reported no remaining Teva Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Centerbridge Partners sold 100,000 Teva Pharmaceuticals shares in Q1 2021, an estimated $965K.
  • Centerbridge Partners first reported a position in Teva Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Centerbridge Partners's Teva Pharmaceuticals position peaked at $1.23M in Q2 2020.
  • 451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2021.

Based on Centerbridge Partners's 13F filing for Q1 2021, filed 17 May 2021.